UNSPSC 51162728: Naphazoline

This classification denotes an alpha-adrenergic agonist with the molecular formula C14H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) H231GF11BV, chemically known as 4,5-dihydro-2-(1-naphthylmethyl)imidazole but more generally known as naphazoline, which bears US NIH Compound Identifier 4436. European Medicines Agency schedules Naphazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09154MIG. The term NAPHAZOLINE is an International Non-Proprietary Name.

UNSPSC 51162728 Naphazoline is a Commodity code for pharmaceutical products, but the recent state and local opportunities tagged to it are actually soliciting naloxone (an opioid antagonist used in overdose reversal) and multi-source generic pharmaceuticals and over-the-counter products through cooperative purchasing frameworks. The code shows a mismatch between its nominal scope and the work actually being procured — naphazoline is a nasal decongestant, while the recent opportunities are for opioid-reversal medications and broader pharmaceutical supply contracts. State and local governments pursuing pharmaceutical supply agreements use cooperative purchasing vehicles and direct competitive bidding; Seminole County, Florida issued an IFB for naloxone and drug deactivation systems, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for generic multi-source pharmaceuticals and OTC products available to multiple state and local government members across participating jurisdictions including Oregon.

The recent activity centers on Florida and the upper Midwest, with Seminole County's July 2026 IFB due July 26, 2026, calling for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The MMCAP RFP, posted January 20, 2026 with proposals due March 26, 2026, seeks manufacturers to supply identified generic pharmaceutical products through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with pricing weighted 75 percent on competitiveness, 10 percent on fixed pricing for contract term, and the remainder on administrative compliance and EDI capability. Both opportunities require manufacturers to maintain cGMP and DSCSA compliance, carry substantial insurance including commercial general liability of $5 million per occurrence for MMCAP vendors, and accept electronic submission through state procurement portals. The code appears to show limited relevant recent activity given the pharmaceutical-nomenclature mismatch; vendors pursuing naloxone or multi-source pharmaceutical contracts should verify code assignments before responding.